Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05013008




Registration number
NCT05013008
Ethics application status
Date submitted
20/07/2021
Date registered
19/08/2021

Titles & IDs
Public title
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
Scientific title
A Non-blinded Retrospective Biomarker add-on Study to FIGARO-DKD for Bioprofiling the Pharmacodynamic Response to Finerenone in FIGARO-DKD Subjects
Secondary ID [1] 0 0
2021-003053-37
Secondary ID [2] 0 0
21952
Universal Trial Number (UTN)
Trial acronym
FIGARO-BM
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Kidney Disease 0 0
Type 2 Diabetes Mellitus 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Finerenone (Kerendia, BAY94-8862)
Treatment: Drugs - Placebo

Experimental: Finerenone - Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.

Placebo comparator: Placebo - Participants received matching placebo once daily in addition to standard of care therapy in previous interventional Phase 3 trial FIGARO-DKD. No new intervention was administered in this biomarker study.


Treatment: Drugs: Finerenone (Kerendia, BAY94-8862)
Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.

Treatment: Drugs: Placebo
Oral tablet; starting at 10 mg or 20 mg; once daily; received in previous interventional Phase 3 trial FIGARO-DKD; no new intervention was administered in this biomarker study.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean Change in Plasma Biomarker Levels After 36 Months of Treatment Versus 4 Months of Treatment in a Set of 27 Pre-defined Biomarkers
Timepoint [1] 0 0
At 4 months (Visit 3) of treatment and 36 months (Visit 11) of treatment

Eligibility
Key inclusion criteria
* This study will only include participants who were enrolled in the FIGARO-DKD study (NCT02545049) and had received up to 20 mg finerenone or placebo for =24 months.
* For each participant, pharmacokinetic (PK) plasma samples from Visit 3 and at least 2 other Visits (Visit 5, Visit 8, Visit 11) must be available on storage from the main study FIGARO-DKD.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participants which did not show overall compliance of 80 to 120% with study intervention in FIGARO-DKD.
* Participants which were not part of the full analysis set (FAS) of FIGARO-DKD.
* Participants with known fatal outcome.
* Participants with baseline estimated glomerular filtration rate (eGFR) =25 mL/min/1.73m^2.
* Participants with low baseline risk (normal albuminuria and eGFR=60 mL/min/1.73m^2).
* Sponsor request (after discussion with the investigator), for reasons such as a significant protocol deviation.

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/08/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
31/12/2021
Sample size
Target
Accrual to date
Final
951
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Illawarra Diabetes Service - Wollongong
Recruitment hospital [2] 0 0
Melbourne Renal Research Group - Reservoir
Recruitment postcode(s) [1] 0 0
2500 - Wollongong
Recruitment postcode(s) [2] 0 0
3073 - Reservoir
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Hawaii
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
Austria
State/province [10] 0 0
Steiermark
Country [11] 0 0
Austria
State/province [11] 0 0
Wien
Country [12] 0 0
Belgium
State/province [12] 0 0
Gent
Country [13] 0 0
Belgium
State/province [13] 0 0
Roeselaere
Country [14] 0 0
Bulgaria
State/province [14] 0 0
Gorna Oryahovitsa
Country [15] 0 0
Bulgaria
State/province [15] 0 0
Plovdiv
Country [16] 0 0
Bulgaria
State/province [16] 0 0
Yambol
Country [17] 0 0
Canada
State/province [17] 0 0
British Columbia
Country [18] 0 0
Canada
State/province [18] 0 0
Quebec
Country [19] 0 0
Czechia
State/province [19] 0 0
Praha 4
Country [20] 0 0
Denmark
State/province [20] 0 0
Aarhus N
Country [21] 0 0
Denmark
State/province [21] 0 0
Esbjerg
Country [22] 0 0
Denmark
State/province [22] 0 0
Hellerup
Country [23] 0 0
Denmark
State/province [23] 0 0
Herlev
Country [24] 0 0
Denmark
State/province [24] 0 0
Holbæk
Country [25] 0 0
Denmark
State/province [25] 0 0
Holstebro
Country [26] 0 0
Denmark
State/province [26] 0 0
København NV
Country [27] 0 0
Denmark
State/province [27] 0 0
Viborg
Country [28] 0 0
Finland
State/province [28] 0 0
Oulu
Country [29] 0 0
Finland
State/province [29] 0 0
Rauma
Country [30] 0 0
Finland
State/province [30] 0 0
Turku
Country [31] 0 0
Hong Kong
State/province [31] 0 0
Hong Kong
Country [32] 0 0
Hong Kong
State/province [32] 0 0
Shatin
Country [33] 0 0
Hong Kong
State/province [33] 0 0
Sheung Wan
Country [34] 0 0
Israel
State/province [34] 0 0
Ashkelon
Country [35] 0 0
Israel
State/province [35] 0 0
Holon
Country [36] 0 0
Israel
State/province [36] 0 0
Jerusalem
Country [37] 0 0
Israel
State/province [37] 0 0
Kfar Saba
Country [38] 0 0
Israel
State/province [38] 0 0
Nazareth
Country [39] 0 0
Israel
State/province [39] 0 0
Tel Aviv
Country [40] 0 0
Italy
State/province [40] 0 0
Emilia-Romagna
Country [41] 0 0
Italy
State/province [41] 0 0
Lombardia
Country [42] 0 0
Japan
State/province [42] 0 0
Chiba
Country [43] 0 0
Japan
State/province [43] 0 0
Ehime
Country [44] 0 0
Japan
State/province [44] 0 0
Fukuoka
Country [45] 0 0
Japan
State/province [45] 0 0
Fukushima
Country [46] 0 0
Japan
State/province [46] 0 0
Hiroshima
Country [47] 0 0
Japan
State/province [47] 0 0
Hokkaido
Country [48] 0 0
Japan
State/province [48] 0 0
Ibaraki
Country [49] 0 0
Japan
State/province [49] 0 0
Ishikawa
Country [50] 0 0
Japan
State/province [50] 0 0
Kanagawa
Country [51] 0 0
Japan
State/province [51] 0 0
Osaka
Country [52] 0 0
Japan
State/province [52] 0 0
Saitama
Country [53] 0 0
Japan
State/province [53] 0 0
Tochigi
Country [54] 0 0
Japan
State/province [54] 0 0
Kumamoto
Country [55] 0 0
Japan
State/province [55] 0 0
Nagasaki
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Gang''weondo
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Gyeonggido
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Seoul Teugbyeolsi
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Seoul
Country [60] 0 0
Netherlands
State/province [60] 0 0
Zwijndrecht
Country [61] 0 0
Portugal
State/province [61] 0 0
Braga
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Arkhangelsk
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Izhevsk
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Kemerovo
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Kirov
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Krasnodar
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Moscow
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Nizhny Novgorod
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Saratov
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Voronezh
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Yaroslavl
Country [72] 0 0
Singapore
State/province [72] 0 0
Singapore
Country [73] 0 0
Spain
State/province [73] 0 0
A Coruña
Country [74] 0 0
Spain
State/province [74] 0 0
Cádiz
Country [75] 0 0
Spain
State/province [75] 0 0
Barcelona
Country [76] 0 0
Spain
State/province [76] 0 0
Madrid
Country [77] 0 0
Sweden
State/province [77] 0 0
Göteborg
Country [78] 0 0
Sweden
State/province [78] 0 0
Uppsala
Country [79] 0 0
Sweden
State/province [79] 0 0
Örebro
Country [80] 0 0
Taiwan
State/province [80] 0 0
Changhua
Country [81] 0 0
Taiwan
State/province [81] 0 0
Kaohsiung
Country [82] 0 0
Taiwan
State/province [82] 0 0
New Taipei City
Country [83] 0 0
Taiwan
State/province [83] 0 0
Taichung
Country [84] 0 0
Taiwan
State/province [84] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT05013008